Companies /Healthcare

Tenaya Therapeutics Inc

NASDAQ: TNYA Biotechnology
$0.55
▲ $0.00 (+0.31%) today
Markets open · 11:45am ET

TNYA at a Glance

Valuation
Market cap
$122.0M
Profitability
Revenue (TTM)
$1.3M
EPS (TTM)
$-0.52
Price
52-week range
$1 – $2
Street target
$3.20
Earnings
Next report
Nov 9, 2026

Headquartered in South San Francisco, CA Fiscal year ends December NASDAQ: TNYA tenayatherapeutics.com

About Tenaya Therapeutics

Tenaya Therapeutics is a clinical-stage biotechnology company focused on discovering, developing, and delivering potentially curative therapies that address the underlying causes of heart disease. Its pipeline includes three clinical-stage candidates: TN-201, a gene therapy for MYBPC3-associated hypertrophic cardiomyopathy (HCM); TN-401, a gene therapy for PKP2-associated arrhythmogenic right ventricular cardiomyopathy (ARVC); and TN-301, a small molecule HDAC6 inhibitor with potential applications in heart failure with preserved ejection fraction (HFpEF) and Duchenne muscular dystrophy (DMD). The company employs modality-agnostic target discovery and validation capabilities to generate novel medicines based on genetic insights for both rare genetic disorders and more prevalent heart conditions. Tenaya trades on NASDAQ under the ticker TNYA and has a collaboration agreement with Alnylam Pharmaceuticals. Updated

TNYA Coverage

Frequently Asked Questions

What does Tenaya Therapeutics do?

Tenaya Therapeutics is a clinical-stage biotechnology company focused on discovering, developing, and delivering potentially curative therapies that address the underlying causes of heart disease.

What is the TNYA stock price target?

The Wall Street consensus 12-month price target for TNYA is $3.20.